Survival rates in pancreatic cancer linked to inverse correlation between specific oncogene and tumor suppressant
A new Tel Aviv University study pinpoints the inverse correlation between a known oncogene — a gene that promotes the development of cancer — and the expression of an oncosuppressor microRNA as the reason for extended pancreatic cancer survival. The study may serve as a basis for the development of an effective cocktail of drugs for this deadly disease and other cancers.
The study, which was published in Nature Communications, was led by Prof. Ronit Satchi-Fainaro, Chair of the Department of Physiology and Pharmacology at TAU’s Sackler Faculty of Medicine, and conducted by Hadas Gibori and Dr. Shay Eliyahu, both of Prof. Satchi-Fainaro’s multidisciplinary laboratory, in collaboration with Prof. Eytan Ruppin of TAU’s Computer Science Department and the University of Maryland and Prof. Iris Barshack and Dr. Talia Golanof Chaim Sheba Medical Center, Tel Hashomer.
Pancreatic cancer is among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients die within just a year of diagnosis. “Despite all the treatments afforded by modern medicine, some 75% of all pancreatic cancer patients die within 12 months of diagnosis, including many who die within just a few months,” Prof. Satchi-Fainaro says.
“But around seven percent of those diagnosed will survive more than five years. We sought to examine what distinguishes the survivors from the rest of the patients,” Prof. Satchi-Fainaro continues. “We thought that if we could understand how some people live several years with this most aggressive disease, we might be able to develop a new therapeutic strategy.”
Calling a nano-taxi
The research team examined pancreatic cancer cells and discovered an inverse correlation between the signatures of miR-34a, a tumor suppressant, and PLK1, a known oncogene. The levels of miR-34a were low in pancreatic cancer mouse models, while the levels of the oncogene were high. This correlation made sense for such an aggressive cancer. But the team needed to see if the same was true in humans.
The scientists performed RNA profiling and analysis of samples taken from pancreatic cancer patients. The molecular profiling revealed the same genomic pattern found earlier in mouse models of pancreatic cancer.
The scientists then devised a novel nanoparticle that selectively delivers genetic material to a tumor and prevents side effects in surrounding healthy tissues.
“We designed a nanocarrier to deliver two passengers: (1) miR-34a, which degrades hundreds of oncogenes; and (2) a PLK1 small interfering RNA (siRNA), that silences a single gene,” Prof. Satchi-Fainaro says. “These were delivered directly to the tumor site to change the molecular signature of the cancer cells, rendering the tumor dormant or eradicating it altogether.
“The nanoparticle is like a taxi carrying two important passengers,” Prof. Satchi-Fainaro continues. “Many oncology protocols are cocktails, but the drugs usually do not reach the tumor at the same time. But our ‘taxi’ kept the ‘passengers’ — and the rest of the body — safe the whole way, targeting only the tumor tissue. Once it ‘parked,’ an enzyme present in pancreatic cancer caused the carrier to biodegrade, allowing the therapeutic cargo to be released at the correct address — the tumor cells.”
Improving the odds
To validate their findings, the scientists injected the novel nanoparticles into pancreatic tumor-bearing mice and observed that by balancing these two targets — bringing them to a normal level by increasing their expression or blocking the gene responsible for their expression — they significantly prolonged the survival of the mice.
“This treatment takes into account the entire genomic pattern, and shows that affecting a single gene is not enough for the treatment of pancreatic cancer or any cancer type in general,” according to Prof. Satchi-Fainaro.
The Latest on: Pancreatic cancer
- Two thousand pancreatic cancer patients die in lockdownon November 29, 2020 at 2:09 am
Sign up for FREE now and never miss the top Royal stories again. Figures collated by Pancreatic Cancer Action, show a 17 percent drop in pancreatic cancer patient survival linked to suspended ...
- Pancreatic Cancer Therapeutics Diagnostics Market Growth Rate and Development Analysis to 2022on November 26, 2020 at 8:09 am
The uncontrolled growth of cells in the pancreas causes pancreatic cancer. It is an abnormal, unrestrained growth of ...
- Pancreatic cancer month - join the fight | Houghtaling and Downeyon November 24, 2020 at 3:46 am
By supporting research, staying vigilant about our own health and risk factors, and making our families and friends aware of this deadly disease, we will help drive the search for hope and a cure." ...
- U.S. pancreatic cancer deaths are expected to total 47,500 in 2020on November 23, 2020 at 6:08 pm
In 2020, deaths from pancreatic cancer in the United States are expected to total 47,500, according to the National Cancer Institute.
- November marks Pancreatic Cancer Awareness Monthon November 23, 2020 at 11:07 am
November is Pancreatic Cancer Awareness Month. Pancreatic cancer is extremely hard to detect and is the third leading cause of cancer-related deaths in the United States. Julie Fleshman, the president ...
- Pancreatic Cancer Market Research Based on COVID 19 and Analysis on Techniques and Applications Report 2020-2027on November 23, 2020 at 1:40 am
The Global Pancreatic Cancer Market is expected to exceed more than US$ 13 billion by 2024. Browse Full Report: Pancreatic cancer is origins by the unrestrained boom of cells within the pancreas.
- Alex Trebek raises awareness of ‘terrible’ pancreatic cancer in pre-recorded ‘Jeopardy!’ videoon November 20, 2020 at 3:39 pm
During the beginning of Thursday’s episode of “Jeopardy!”, the late veteran TV personality shared a pre-taped message on the day dedicated to raising awareness and funds for pancreatic cancer.
- Alex Trebek spreads awareness about 'terrible' pancreatic cancer on pre-recorded 'Jeopardy!'on November 20, 2020 at 8:33 am
In honor of World Pancreatic Cancer Day, "Jeopardy!" aired a pre-recorded show featuring Alex Trebek's touching message about pancreatic cancer.
- The University of Verona and IntraOp® Announce PancFORT Trial for Pancreatic Canceron November 20, 2020 at 3:41 am
IntraOp Medical Corporation and the University of Verona in Italy announced today the enrollment of the first patient in the PancFORT Trial: A phase II study of primary chemotherapy, stereotactic body ...
- Pancreatic Cancer Collective Announces New PSA Campaign With Keesha Sharp To Raise Awareness About Pancreatic Cancer Clinical Trialson November 20, 2020 at 1:23 am
The Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation and Stand Up To Cancer (SU2C), announced today the launch of a new public service announcement (PSA) campaign, in ...
via Google News and Bing News